Influence on survival of p24 antigen levels in patients with AIDS or advanced AIDS related complex treated with zidovudine. 1992

L Zamora, and J M Gatell, and J M Barrera, and G Ercilla, and C Gil, and E Buira, and J M Miro, and E Soriano
Infectious Disease Unit, University Hospital, Faculty of Medicine, Barcelona, Spain.

In a prospective study sixty-eight patients consecutively diagnosed as having AIDS or advanced ARC who were started on zidovudine therapy were followed up for a median period of 725 days. In the 20 patients who had a baseline p24 antigen level above 20 pg/ml, there was a statistically significant trend towards reduction of the p24 antigen levels after the first month of treatment. The median time of survival of the 68 patients was 702 days and the median symptom-free period was 510 days. Treatment with zidovudine significantly reduced the p24 antigen levels. However, the life expectancy and the symptom-free period were not statistically different in the patients with p24 antigen levels always below or with levels always above two arbitrarily chosen cut-off points of 20 pg/ml and 50 pg/ml, respectively.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000386 AIDS-Related Complex A prodromal phase of infection with the human immunodeficiency virus (HIV). Laboratory criteria separating AIDS-related complex (ARC) from AIDS include elevated or hyperactive B-cell humoral immune responses, compared to depressed or normal antibody reactivity in AIDS; follicular or mixed hyperplasia in ARC lymph nodes, leading to lymphocyte degeneration and depletion more typical of AIDS; evolving succession of histopathological lesions such as localization of Kaposi's sarcoma, signaling the transition to the full-blown AIDS. ARC,Lymphadenopathy Syndrome,AIDS Related Complex,Complex, AIDS-Related,Lymphadenopathy Syndromes,Syndrome, Lymphadenopathy,Syndromes, Lymphadenopathy
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D016655 HIV Core Protein p24 A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by ELISA and Western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines. HIV Major Core Protein p24,HIV gag Gene Product p24,HIV p24 Antigen,gag Protein p24, HIV,p24(HIV),HIV Protein p24,HTLV-III p24,p24 protein, Human Immunodeficiency Virus,HTLV III p24,p24 Antigen, HIV,p24, HIV Protein,p24, HTLV-III

Related Publications

L Zamora, and J M Gatell, and J M Barrera, and G Ercilla, and C Gil, and E Buira, and J M Miro, and E Soriano
September 1990, AIDS (London, England),
L Zamora, and J M Gatell, and J M Barrera, and G Ercilla, and C Gil, and E Buira, and J M Miro, and E Soriano
January 1989, Journal of clinical laboratory analysis,
L Zamora, and J M Gatell, and J M Barrera, and G Ercilla, and C Gil, and E Buira, and J M Miro, and E Soriano
August 1992, AIDS (London, England),
L Zamora, and J M Gatell, and J M Barrera, and G Ercilla, and C Gil, and E Buira, and J M Miro, and E Soriano
January 1991, BMJ (Clinical research ed.),
L Zamora, and J M Gatell, and J M Barrera, and G Ercilla, and C Gil, and E Buira, and J M Miro, and E Soriano
December 1988, Lancet (London, England),
L Zamora, and J M Gatell, and J M Barrera, and G Ercilla, and C Gil, and E Buira, and J M Miro, and E Soriano
May 1988, JAMA,
L Zamora, and J M Gatell, and J M Barrera, and G Ercilla, and C Gil, and E Buira, and J M Miro, and E Soriano
November 1989, Clinical pharmacology and therapeutics,
L Zamora, and J M Gatell, and J M Barrera, and G Ercilla, and C Gil, and E Buira, and J M Miro, and E Soriano
August 1990, The Netherlands journal of medicine,
L Zamora, and J M Gatell, and J M Barrera, and G Ercilla, and C Gil, and E Buira, and J M Miro, and E Soriano
January 1989, AIDS (London, England),
L Zamora, and J M Gatell, and J M Barrera, and G Ercilla, and C Gil, and E Buira, and J M Miro, and E Soriano
November 1989, JAMA,
Copied contents to your clipboard!